men, 1,800
Early evidence suggests that GLP-1s can also help people with breast cancer and obesity lose weight, which may improve their prognosis

Key Takeaways No commercial retatrutide pen exists: Eli Lilly has not FDA-approved or publicly released any branded retatrutide auto-injector as of May 2026 Phase 3 TRIUMPH trials confirm subcutaneous injection once weekly, but the specific device format has not been disclosed by Lilly Grey-market pens are not Lilly products: The "SALKALLI" DailyMed entry is a Chinese export-only product (Guangzhou Yixin Co.), not FDA-approved for US use Phase 3 TRIUMPH-4 results showed 28.7% weight loss at 68 weeks on 12mg, the strongest obesity trial result on record When approved (2027 earliest), a once-weekly auto-injector similar to Lilly's KwikPen format is widely anticipated Use the retatrutide pharmacokinetic calculator to plan dosing regardless of delivery format 28.7% Phase 3 TRIUMPH-4 Weight Loss ~6 days Half-Life (Once-Weekly Dosing) 12mg Maximum Dose (Phase 3) 2027 Earliest Likely US Launch Does Retatrutide Come in a Pen

I was finally able to get the knee surgery I needed, but couldnt have until I lost weight
A small observational study found that patients who timed injections before their largest meal experienced 812% greater early satiety compared to random timing, though this was not a controlled trial
Review Article OPEN ACCESS Lun-Gen Lu * Author information Abstract Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently a pressing public health issue associated with adverse outcomes such as cirrhosis, malignancy, transplantation, and mortality